BioVie, Inc. (BIVI)
| Market Cap | 245.79M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -30.96M |
| Shares Out | 27.21M |
| EPS (ttm) | -6.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,164,291 |
| Open | 7.94 |
| Previous Close | 8.05 |
| Day's Range | 4.11 - 7.94 |
| 52-Week Range | 1.33 - 8.26 |
| Beta | 2.67 |
| Analysts | Buy |
| Price Target | 9.18 (+67.2%) |
| Earnings Date | Nov 9, 2022 |
About BIVI
BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer'... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for BIVI stock is "Buy." The 12-month stock price forecast is 9.18, which is an increase of 67.21% from the latest price.
News
BioVie's Phase 3 Trial Assessing NE3107 in Alzheimer's Disease Has Fully Enrolled the Targeted 316 Patients
Company is Opting to Increase Study Size to 400 due to Fast Enrollment Pace Company is Opting to Increase Study Size to 400 due to Fast Enrollment Pace
Are Medical Stocks Lagging BioVie (BIVI) This Year?
Here is how BioVie Inc. (BIVI) and Immunovant, Inc. (IMVT) have performed compared to their sector so far this year.
BioVie to Present Data from Investigator-Sponsored Exploratory Biomarker and Imaging Trial of NE3107 for the Treatmen...
CARSON CITY, Nev., Nov. 15, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurologic...
Wall Street Analysts Think BioVie Inc. (BIVI) Could Surge 84%: Read This Before Placing a Bet
The mean of analysts' price targets for BioVie Inc. (BIVI) points to an 84% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst...
Is BioVie (BIVI) Stock Outpacing Its Medical Peers This Year?
Here is how BioVie Inc. (BIVI) and Immunovant, Inc. (IMVT) have performed compared to their sector so far this year.
BioVie to Present Data on Characterizing Hospitalization Burden of Ascites at AASLD Liver Meeting 2022
CARSON CITY, Nev., Oct. 24, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurologic...
BioVie's Phase 2 Trial Assessing NE3107's Pro-motoric Activity in Parkinson's Disease is Fully Enrolled
Topline Data Expected December 2022 Topline Data Expected December 2022
BioVie Issues Letter to Shareholders
CARSON CITY, Nev., Oct. 04, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced l...
BioVie to Participate in Cantor Fitzgerald's Neurology & Psychiatry Conference
RENO, Nev., Sept. 29, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver ...
BioVie Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
ORLANDO, FL / ACCESSWIRE / September 15, 2022 / RedChip Companies will air a new interview with BioVie Inc. (NASDAQ:BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug the...
BioVie (BIVI) Stock Pops on Positive Alzheimer's Trial Results
In a fresh press release from this morning, BioVie (NASDAQ: BIVI ) disclosed top-line results from a Phase 2 clinical trial for its Alzheimer's disease treatment, NE3107. The results were largely positi...
BioVie shares soar 19% premarket after company announces positive results from Phase 2 trial of Alzheimer's treatment
BioVie Inc. shares BIVI, +22.42% rose 19% in premarket trade Wednesday, after the biotech announced positive results from a Phase 2 trial of its Alzheimer's Disease treatment NE3107. Moving away from th...
BioVie and Dr. Sheldon Jordan Jointly Announce Topline Results from an Investigator-Sponsored Exploratory Biomarker a...
BioVie Provides Updates on Other Clinical Programs BioVie Provides Updates on Other Clinical Programs
BioVie Announces Patent Issuance Covering Ascites Treatment with BIV201
CARSON CITY, Nev., June 23, 2022 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver...
BioVie to Participate at the B. Riley Securities' Neuro & Ophthalmology Conference
CARSON CITY, Nev., April 25, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced...
BioVie Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report®
CARSON CITY, Nev., March 10, 2022 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurologic...
BioVie to Participate at the Oppenheimer Virtual Annual Healthcare Conference
RENO, Nev., March 09, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver ...
BioVie Announces Treatment of First Patient in Phase 2 Clinical Trial of NE3107 for the Treatment of Parkinson's Disease
RENO, Nev., Jan. 20, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver di...
BioVie to Participate at the LifeSci Partners 11th Annual Corporate Access Event
RENO, Nev., Dec. 28, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver d...
BioVie Announces Partnership with the American Liver Foundation
Campaign to Improve Education on Ascites Due to Liver Cirrhosis and Raise Awareness of BioVie's Phase 2b Study of BIV201 for Refractory Ascites Campaign to Improve Education on Ascites Due to Liver Cirr...
BioVie Secures Up to a $25.0 Million Debt Facility with Avenue Venture Opportunities Fund, L.P. and Avenue Venture Op...
RENO, Nev., Dec. 01, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and ...
BioVie Hosting Key Opinion Leader Webinar on Complications of Advanced Liver Cirrhosis and BIV201 Phase 2b Clinical T...
Thursday, November 11th @ 1:00pm ET Thursday, November 11th @ 1:00pm ET
BioVie Announces the Appointment of a New Chief Medical Officer
Dr. Joseph M. Palumbo, Distinguished Pharma Industry Veteran, to Oversee Development Programs in Neurodegenerative and Liver Disease Dr. Joseph M. Palumbo, Distinguished Pharma Industry Veteran, to Over...
Why Did BioVie Shares Jump 21% Today?
The FDA has signed off BioVie Inc's (NASDAQ: BIVI) Phase 2 study assessing NE3107's potential pro-motoric impact in Parkinson's disease patients. The NM201 study is a double-blind, placebo-controlled, s...
BioVie Announces FDA Authorization to Initiate Phase 2 Trials Assessing NE3107's Pro-motoric Activity in Parkinson's ...
SANTA MONICA, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurolo...